[ November 2007 ]
Sanofi-aventis and DNDi held a symposium on the implementation of a new artemisinin combination therapy (ACT) in African endemic countries. Over 120 attendees from NGOs, academia, and the pharmaceutical sector heard presentations by FACT project partners on ASAQ and ASMQ. In addition, DNDi also presented the ethical considerations of malaria field studies, and screening of natural products against infectious disease pathogens.
[ November 2007 ]
[ September 2007 ]
DNDi and the Leishmaniasis East Africa Platform (LEAP) organised a scientific symposium on visceral leishmaniasis (VL): “A step together in the right direction” at the centenary meeting of the Royal Society of Tropical Medicine and Hygiene (RSTMH), in London. More than 120 scientists attended the meeting.
[ June 2007 ]
The PAN4ND Annual Meeting was held at Shanghai Institute Materia Medica, 4th-6th June 2007, and included three sessions: The Annual Meeting of the Pan-Asian Screening Network; the Natural Product Working Group, and the Natural Product Symposium.
[ May 2007 ]
Amsterdam, The Netherlands
DNDi, in two presentations, discussed how Product Development Partnerships could deliver innovative treatments to patients, and the sanofi-aventis / DNDi Partnership against malaria, at the 5th ECTMIH from 24 to 28 May in Amsterdam.
[ March 2007 ]
Sanofi-aventis and DNDi launched ASAQ, the new fixed-dose combination of artesunate (AS) and amodiaquine (AQ), which is now available in 21 countries throughout sub-Saharan Africa (June 08). ASAQ, the first drug developed by DNDi, is an innovative product to treat malaria that is adapted to the needs of patients of all ages, simple to use, accessible as a non patented drug, and available at an affordable price.